ArticleFrontiers in medicine2025
Predicting estrogen receptor status from HE-stained breast cancer slides using artificial intelligence.
Article in Frontiers in medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- An agentic framework for autonomous scientific discovery in cancer pathology.Nature medicine · 2026Article
- How artificial intelligence applied to digital pathology could guide treatment personalization in breast cancer.ESMO real world data and digital oncology · 2026Review
- Development and internal validation of a task-conditioned multimodal radiology-pathology model for breast cancer staging and biomarker profiling: a retrospective cohort study.Frontiers in cell and developmental biology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: The estrogen receptor (ER) is routinely assessed by immunohistochemistry (IHC) in breast cancer to stratify patients into therapeutic and prognostic groups. Pathology laboratories are burdened by an increased number of biopsies, and costly and resource-demanding molecular pathology analyses. Automatic, artificial intelligence-based prediction of biological properties from hematoxylin and eosin (HE)-stained slides could increase efficiency and potentially reduce costs at laboratories. The aim of this study was to develop a model for prediction of ER status from HE-stained tissue microarrays (TMAs). Our methodology can be used as proof-of-concept for the prediction of more complex and costly molecular analyses in cancer. Methods: In this study, TMAs from more than 2,000 Norwegian breast cancer patients were used to train and predict ER status using the clustering-constrained attention multiple-instance learning (CLAM) framework. Two patch sizes were evaluated, multi-branch and single-branch CLAM configurations were compared, and a comprehensive hyperparameter search with more than 16 000 experiments was performed. The models were evaluated on internal and external test sets. Results: On the internal test set, the proposed model achieved a micro accuracy, a macro accuracy, and an area under the curve of 0.91, 0.86, and 0.95, respectively. The corresponding results on the external test set were 0.93, 0.76, and 0.91, respectively. Using larger patch sizes resulted in significantly better classification performance, while no significant differences were observed when changing CLAM configurations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.